title: Using bradykinin-potentiating peptide structures to develop new antihypertensive drugs.
abstract: Angiotensin I-converting enzyme (ACE) is a dipeptidyl-carboxypeptidase expressed in endothelial, epithelial and neuroepithelial cells. It is composed of two domains, known as N- and C-domains, and it is primarily involved in blood pressure regulation. Although the physiological functions of ACE are not limited to its cardiovascular role, it has been an attractive target for drug design due to its critical role in cardiovascular and renal disease. We examined natural structures based on bradykinin-potentiating peptides (BPPs) extracted from Bothrops jararaca venom for ACE inhibition. Modeling, docking and molecular dynamics were used to study the conserved residues in the S2', S1' and S1 positions that allow enzyme-substrate/inhibitor contacts. These positions are conserved in other oligopeptidases, and they form tight and non-specific contacts with lisinopril, enalapril and BPP9a inhibitors. The only specific inhibitor for human somatic ACE (sACE) was BPP9a, which is instable in the N-sACE-BPP9a complex due to repulsive electrostatic interactions between Arg P4-Arg 412 residues. Specificity for the C-terminal domain in human sACE inhibition was confirmed by electrostatic interaction with the Asp 1008 residue. Peptide-like BPP structures, naturally developed by snakes across millions of years of evolution, appear to be good candidates for the development of domain-selective ACE inhibitors with high stability and improved pharmacological profiles.
authors.affiliation: Center of Applied Toxinology, Instituto Butantan, São Paulo, SP, Brazil jorgehf@butantan.gov.br
authors.forename: Jorge Hernandez
authors.initials: JH
authors.lastname: Fernandez
authors.forename: Goran
authors.initials: G
authors.lastname: Neshich
authors.forename: Antonio Carlos M
authors.initials: AC
authors.lastname: Camargo
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000737:chemistry*; D000818:Animals; D000959:Antihypertensive Agents / Q000737:chemistry*; D017837:Bothrops; D001920:Bradykinin / Q000737:chemistry*; D020134:Catalytic Domain; D003435:Crotalid Venoms / Q000737:chemistry*; D015195:Drug Design; D004357:Drug Synergism; D006801:Humans; D008958:Models, Molecular; D009842:Oligopeptides / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D013379:Substrate Specificity
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D003435:Crotalid Venoms; D009842:Oligopeptides; C006791:bradykinin potentiating factors; D001920:Bradykinin